Cargando…

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice

BACKGROUND: Therapies targeted towards the tumour vasculature can be exploited for the purpose of improving the systemic delivery of oncolytic viruses to tumours. Photodynamic therapy (PDT) is a clinically approved treatment for cancer that is known to induce potent effects on tumour vasculature. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, M, Bieniasz, M, Seshadri, M, Fisher, D, Ciesielski, M J, Chen, Y, Pandey, R K, Kozbor, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242530/ https://www.ncbi.nlm.nih.gov/pubmed/21989183 http://dx.doi.org/10.1038/bjc.2011.429

Ejemplares similares

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
por: Golding, J P, et al.
Publicado: (2013)

A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy
por: Castano, A P, et al.
Publicado: (2006)

Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice
por: Martikainen, Miika, et al.
Publicado: (2017)

Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen
por: Reginato, E, et al.
Publicado: (2013)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin
por: Korbelik, M, et al.
Publicado: (2007)

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
por: Šímová, J, et al.
Publicado: (2011)

CD8(+) T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4(+) T cells and dependent on natural killer cells
por: Kabingu, E, et al.
Publicado: (2007)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells
por: Laptev, R, et al.
Publicado: (2006)

Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation
por: Dorward, A M, et al.
Publicado: (2005)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy
por: Miao, L, et al.
Publicado: (2014)

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro
por: Etminan, N, et al.
Publicado: (2011)

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
por: Byrne, A T, et al.
Publicado: (2009)

Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid
por: Niedre, M J, et al.
Publicado: (2005)

Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer
por: de Souza, Ana Luiza Ribeiro, et al.
Publicado: (2016)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model
por: Wright, K E, et al.
Publicado: (2009)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells
por: Sinha, A K, et al.
Publicado: (2006)

Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin
por: Dietze, A, et al.
Publicado: (2005)

Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling
por: Wei, L-H, et al.
Publicado: (2007)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_341ia1fcpkubv6prlasnromct5